Publicaciones en las que colabora con Pablo Miguel Barreiro García (30)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  3. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2011

  1. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C

    Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295

  2. Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance

    Journal of Viral Hepatitis, Vol. 18, Núm. 1, pp. 11-16

2010

  1. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  2. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  2. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

    AIDS, Vol. 23, Núm. 6, pp. 689-696

  3. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients

    HIV Medicine, Vol. 10, Núm. 1, pp. 53-59

2008

  1. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 200-205

  2. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 3, pp. 699-704

  3. Risk for immune-mediated liver reactions by nevirapine revisited

    AIDS Reviews, Vol. 10, Núm. 2, pp. 110-115

2007

  1. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 469-476